Quick answer
How is lyophilized IGF-1 LR3 reconstituted for laboratory work? Handle it as a protein, not a short peptide. Let the sealed vial reach room temperature, spin the powder down, add the chosen sterile solvent slowly down the wall of the vial, and let it dissolve with gentle swirling rather than shaking or vortexing. Many protein reagents are first taken up in a mildly acidic solvent and then diluted into a buffer with a carrier protein to limit loss to plastic; confirm the solvent against the lot documentation. Stock concentration is mass divided by final volume, which the reconstitution calculator does for you. Divide the stock into single-use aliquots and record every step.
The IGF-1 LR3 product page lists a 1 mg lyophilized powder in a sealed clear glass vial. The molecule is 83 amino acids and about 9 kDa, with disulfide bonds holding its fold. That puts it between a short synthetic peptide and a full-size protein, and its handling rules are closer to those of a recombinant growth factor than to the rules for a 10-residue peptide. This guide covers the reasoning behind each reconstitution step for the laboratory researcher, including the formula for concentration. It makes no recommendation about use outside the laboratory. For laboratory research use only; not for human consumption.
Why a protein needs different handling from a short peptide
Short peptides are chemically robust and usually tolerate vortexing, repeated warming and ordinary plastic. A disulfide-bonded protein does not. Three properties drive the differences.
- A folded structure that can be lost. Vigorous agitation introduces air–liquid interface, where proteins can unfold and aggregate (Mahler et al., 2009).
- Strong tendency to adsorb to surfaces. At low concentrations a large fraction of dissolved protein can end up on tube walls and pipette tips; the effect is documented for peptides and proteins alike and is the reason low-binding plasticware and carrier proteins are routine (Goebel-Stengel et al., 2011).
- Chemical vulnerabilities. Oxidation, deamidation and disulfide exchange are the usual degradation routes for protein reagents and are accelerated by warmth, extreme pH and repeated handling (Wang, 1999; Manning et al., 2010).
None of this is exotic. It means the extra care is mostly about gentleness and about making dilute solutions stable, not about special equipment. The molecule's structure is described in the IGF-1 LR3 explainer and the research overview.
Before opening the vial
Gather everything first so the vial is open for the shortest possible time.
- Take the sealed vial from refrigerator or freezer storage and let it reach room temperature in its closed state; opening a cold vial draws in moist air that condenses on the powder.
- Check the label, lot number and vial integrity, and record them. Powder displaced onto the vial wall or stopper in transit is normal for lyophilized material (see what is normal in a vial).
- Briefly centrifuge or tap the vial so all the powder sits at the bottom.
- Prepare sterile solvent, low-binding tubes, and the carrier-protein buffer if one will be used.
- Wipe the stopper with alcohol and let it dry.
Background on why the powder arrives as a lyophilized cake is in what is lyophilization, and the general steps are in how to reconstitute a lyophilized peptide.
Choosing a solvent and a carrier
The correct solvent depends on the lot documentation and on what the stock will be used for. The table sets out the common options in terms of what each does and what to watch for. It is a decision aid, not a protocol.
| Option | What it does | Watch for |
|---|---|---|
| Sterile water | Dissolves the powder with no added salts or preservatives | Final pH depends on residual counterions; stocks are short-lived at neutral pH |
| Dilute acid (for example, a low-millimolar hydrochloric or acetic acid solution) | Commonly used for the first dissolution of recombinant growth factors because many dissolve and stay stable at low pH | Dilute into buffered medium before adding to cells so the acid is not carried over |
| Bacteriostatic water | Contains a preservative; used for multi-draw research stocks | Preservative can affect cells and some assays; see bacteriostatic water explained |
| Buffer with carrier protein (for example, albumin at about 0.1%) | Limits adsorption and stabilizes dilute working stocks | Carrier can interfere with some analytical readouts and adds a protein to defined media |
Practice for recombinant growth factors is to make a concentrated primary stock in the solvent given in the lot paperwork, then dilute into carrier-containing buffer for working stocks. Where the lot documentation is silent, run a small pilot with a portion of the material before committing the whole vial. The bacteriostatic water product page and the mixing guide explain the preserved option in more detail.
Mixing: slow, gentle, no foam
Add the solvent slowly, directed at the inside wall of the vial rather than onto the powder. Let it run down and wet the cake, then swirl the vial gently or rock it. Do not shake, vortex or draw the solution repeatedly through a narrow tip. A protein can take several minutes to dissolve fully; waiting is better than forcing it. If foam forms, let it settle rather than pipetting it. After dissolution, the solution should be clear and colorless; haze or particles are covered in the cloudy-vial guide. If particles remain, record them and do not filter blindly, because filter membranes can adsorb a substantial share of dilute protein.
Concentration arithmetic as a formula
Stock concentration is a simple ratio. Use consistent units and write the working out in the lab notebook.
| Quantity | Formula | Note |
|---|---|---|
| Stock concentration | C = m / V | m is the labeled mass in the vial, V is the final solution volume |
| Volume needed for a target concentration | V = m / C | Solve for the diluent volume to add to the vial |
| Working dilution | C1 × V1 = C2 × V2 | C1 is the stock, C2 the target, V2 the final volume, V1 the stock volume to take |
| Molar concentration | c = (m / M) / V | M is molar mass, about 9.1 kDa for this analog; convert units carefully |
| Mass per aliquot | m_aliquot = C × V_aliquot | Use to confirm that aliquots sum to the vial content |
Two cautions apply. The labeled mass is gross powder weight, so the true protein content can be somewhat lower because of counterions and water; confirm by absorbance if exact concentration matters. And extremely small volumes are hard to pipette accurately, so an intermediate dilution is better than a single large step. The reconstitution calculator performs these conversions, and the volume calculation guide and calculator walkthrough show the logic.
Aliquoting and storage after dissolution
Protein stocks should be divided into single-use portions in low-binding tubes before anything is frozen, because repeated freeze–thaw adds physical stress and each thaw exposes the stock to warm temperatures. Label each tube with compound, concentration, date and lot, keep the aliquots at the lowest practical temperature the lot documentation allows, and thaw one at a time on ice or in the refrigerator. Do not refreeze a thawed aliquot. The product page states that the supplied powder is held at 2–8 °C, with −20 °C for long-term holding, protected from heat, moisture and light; dissolved material follows its own, shorter, limits, discussed in how long reconstituted peptides last and storing research peptides.
Mistakes that reduce the active concentration
- Vortexing or vigorous pipetting, which can unfold and aggregate the protein.
- Dissolving directly into dilute buffer without carrier, then storing in standard polystyrene.
- Leaving the working stock at room temperature for long periods.
- Using a very acidic stock directly on cells without dilution into buffered medium.
- Refreezing thawed aliquots.
- Filtering a small volume of dilute solution through a membrane without a carrier present.
- Relying on nominal mass for a quantitative experiment without a concentration check.
Planning the stock before opening the vial
Decide the number of experiments the vial must cover before dissolving it. A 1 mg vial dissolved into a small volume gives a concentrated primary stock that is easier to keep stable than many dilute ones, and the dilution to working concentration can be done fresh at each session. Write down the intended aliquot count and volume, check with the formulas above that the aliquots add up to the full vial content, and leave a small reserve aliquot for a later activity or concentration check. This planning step is cheap and prevents the most common waste: a stock made too dilute, then stored, then partly lost to adsorption.
Record keeping and verification
Record the lot, solvent and its lot number, final volume, calculated concentration, who prepared it, and the freezer location of every aliquot. If the experiment depends on activity, run a simple functional check on the stock, as described in the purity testing guide, and keep the result with the lot. Certificates, where published, are listed in the COA library; see how to read a COA for what each line means.
Related reading
- IGF-1 LR3 product page
- IGF-1 LR3 research overview
- IGF-1 LR3 explained
- How to reconstitute a lyophilized peptide
- Reconstitution volume calculations
- Storing research peptides
- Reconstitution calculator
- COA library
Frequently asked questions
Why can't I vortex IGF-1 LR3?
It is a folded, disulfide-bonded protein. Vigorous agitation creates air–liquid interfaces where proteins can unfold and aggregate, so gentle swirling is used instead.
What solvent is used for IGF-1 LR3?
It depends on the lot documentation and the application. Recombinant growth factors are often first dissolved in a mildly acidic solvent and then diluted into buffer with carrier protein; sterile water and bacteriostatic water are other options.
Why add a carrier protein?
At low concentrations, much of a dissolved protein can adsorb to tube walls. A carrier such as albumin occupies those sites and stabilizes the working stock.
How do I calculate stock concentration?
Divide the labeled mass by the final volume, C = m / V. The calculator on the site performs the unit conversions.
Is the labeled mass the same as protein content?
Not exactly. It is gross powder mass, so net protein can be lower. Confirm by absorbance or a colorimetric assay when exact concentration matters.
Should I filter the solution?
Only with care. Membranes can adsorb a large share of dilute protein, so filtering is better done on a carrier-containing solution than on a bare dilute stock.
Why aliquot before freezing?
Repeated freeze–thaw adds stress and warmth exposure. Single-use portions let each tube be thawed once.
What should the solution look like?
Clear and colorless with no particles. Haze or strands should be recorded and investigated before use.
How long does reconstituted IGF-1 LR3 stay usable?
There is no single figure. It depends on solvent, concentration, carrier, temperature and handling, and is best checked with a functional assay in your own system.
Where do I find storage conditions for the powder?
On the product page: refrigerate at 2–8 °C, −20 °C for long-term, protect from heat, moisture and light.
Related reading: IGF-1 LR3 Complete Guide: Where the Research Fits, IGF-1 LR3 Storage & Stability: Degradation Routes, IGF-1 LR3 Structure: Sequence Changes Explained.
References
- Mahler HC, Friess W, Grauschopf U, Kiese S. Protein aggregation: pathways, induction factors and analysis. J Pharm Sci. 2009;98(9):2909-2934. doi:10.1002/jps.21566
- Goebel-Stengel M, Stengel A, Taché Y, Reeve JR Jr. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm. 1999;185(2):129-188. doi:10.1016/S0378-5173(99)00152-0
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. doi:10.1007/s11095-009-0045-6
- Clemmons DR. Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol Cell Endocrinol. 1998;140(1-2):19-24. doi:10.1016/s0303-7207(98)00024-0
- Bayne ML, Applebaum J, Chicchi GG, et al. Structural analogs of human insulin-like growth factor I with reduced affinity for serum binding proteins and the type 2 IGF receptor. J Biol Chem. 1988;263(13):6233-6239. doi:10.1016/s0021-9258(18)68777-0
